medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2011, Number 5

<< Back Next >>

Rev Invest Clin 2011; 63 (5)

Rituximab: a new therapeutic alternative in Grave’s disease

Tello-Winniczuk N, Díaz-Jouanen E

Language: Spanish
References: 35
Page: 536-543
PDF size: 142.32 Kb.


ABSTRACT

Graves’ disease is the most frequent cause of hyperthyroidism, affecting mainly young aged women, with an etiology of autoimmune basis. One of its manifestations, Graves’ ophthalmopathy whose pathophysiology is unknown, represents one of the greatest therapeutic challenges in these patients, because they require aggressive treatment with steroids and multiple subsequent reconstructive surgeries in certain cases. It also represents a high burden to the health system. Drugs targeting B cells have been very effective for many autoimmune diseases. Rituximab is a murine humanized monoclonal antibody against CD20 + cells currently being studied in various autoimmune diseases including Graves’ disease. The objective of this paper is to expose possible mechanisms by which rituximab could act in both hyperthyroidism and ophthalmopathy of Graves’ disease, as well as the experience with its use acquired so far. The employment of rituximab in recently diagnosed patients or with mild ophthalmopathy is questionable with the evidence available today, however, we think that it may have a role in refractory cases or those who have a contraindication for steroid use.


REFERENCES

  1. Brent GA. Graves’ Disease. N Engl J Med 2008; 358: 2594- 605.

  2. Bahn RS. Pathophysiology of Graves’ ophthalmopathy: The cycle of disease. J Clin Endocrinol Metab 2003; 88: 1939-46.

  3. Dickinson AJ, Perros P. Thyroid-associated orbitopathy: Who and how to treat. Endocrinol Metab Clin N Am 2009; 38: 373-88.

  4. Garrity JA, Bahn RS. Pathogenesis of Graves’ ophthalmopathy: Implications for prediction, prevention, and treatment. Am J Ophthalmol 2006; 142: 147-53.

  5. Smith T, Tsai C, Shih M, Tsui S, Chen B, et al. Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid 2008; 18(9): 983-8.

  6. Bahn RS. Graves’ Ophthalmopathy. N Engl J Med 2010; 362: 726-38.

  7. Pappa A, Calder V, Ajjan R, Fells P, Ludgate M, et al. Analysis of extraocular muscle-infiltrating T cells in thyroid-associated ophthalmology (TAO). Clin Exp Immunol 1997; 109: 362-9.

  8. Eckstein AK, Quadbeck B, Tews S, Mann K, Krüger C, et al. Thyroid associated ophthalmopathy: evidence for CD4+γδ T cells; de novo differentiation of RFD7+ macrophages, but not of RFD1+ dendritic cells; and loss of γδ and αβ T cell receptor expression. Br J Ophthalmol 2004; 88: 803-8.

  9. Aniszewski JP, Valyasevi RW, Bahn RS. Relationship between disease duration and predominant orbital T cell subset in Graves’ ophthalmopathy. J Clin Endocrinol Metab 2000; 85: 776-80.

  10. Khanna D, Chong KL, Afifiyan NF, Hwang CJ, Lee DK, et al. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmol 2010; 117: 133-9.

  11. McLachlan SM, Nagayama Y, Rapoport B. Insight into Graves’ hyperthyroidism from animal models. Endocr Rev 2005; 26: 800-32.

  12. Bartalena L. What to do for moderate-to-severe and active Graves’ orbitopathy if glucocorticoids fail? Clinical Endocrinol 2010; 73: 149-52.

  13. Bartalena L, Lai A, Compri E, Marcocci C, Tanda M. Novel immunomodulating agents for graves orbitopathy. Ophthal Plast Reconstr Surg 2008; 24: 251-6.

  14. Bartalena L, Bladeschi L, Dickinson AJ, Eckstein A, Kendall- Taylor P, et al. Consensus Satement of the European Group on Graves’ Orbitopathy (EUGOGO) on Management of Graves’ Orbitopathy. Thyroid 2008; 18: 333-46.

  15. Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, Ezrachi D, Shimon I, et al. Treatment modalities for Graves’ ophthalmopathy: systematic review and metaanalysis. Clin Endocrinol Metab 2009; 94: 2708-16.

  16. Gürcan M, Keskin D, Stern J, Nitzberg M, Shekhani H, et al. A review of the current use of rituximab in autoimmune diseases. Int Immunopharm 2009; 9: 10-25.

  17. Levesque MC. Translational mini-review series on B cell-directed therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol 2009; 157: 198-208.

  18. Liossis CS, Sfikakis PP. Rituximab-induced B cell depletion in autoimmune diseases: Potential effects on T cells. Clin Immunol 2008; 127: 280-5.

  19. Vigna-Pérez M, Hernández-Castro B, Paredes-Saharopulos O, Portales-Pérez D, Baranda L, et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006; 8(3): R83.

  20. El Fassi D, Nielsen CH, Hasselbalch HC, Hegedüs L. The rationale for B lymphocyte depletion in Graves’ disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur J Endocrinol 2006: 154; 623-32.

  21. Levesque MC, St. Clair EW. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. J Allergy Clin Immunol 2008; 121: 13-21.

  22. Raterman H. Rituximab and thyroid function. Arch Intern Med 2009; 169: 1073-4.

  23. El Fassi D, Nielsen CH, Kjeldsen J, Clemmensen O, Hegedüs L. Ulcerative colitis following B lymphocyte depletion with rituximab in Graves Disease. Gut 2008; 57: 714-5.

  24. Looney RJ. Treating human autoimmune disease by depleting B cells. Ann Rheum Dis 2002; 61: 863-6.

  25. El Fassi D, Clemmensen O, Nielsen CH, Silkiss RZ, Hegedüs L. Image in endocrinology: Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves’ disease. J Clin Endocrinol Metab 2007; 92: 3762-3.

  26. Salvi M, Vannucchi G, Campi I, Curro N, Simonetta S, et al. Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: Effects on orbital lymphocytic infiltrates. Clin Immunol 2009; 131: 360-5.

  27. Salvi M, Vannucchi G, Campi I, Rossi S, Bonara P, et al. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur J Endocrinol 2006; 154: 511–7.

  28. Heemstra K, Toes RE, Sepers J, Pereira A, Corssmit E, et al. Rituximab in relapsing Graves’ disease, a phase II study. Eur J Endocrinol 2008; 159: 609-15.

  29. Rodien P. Rituximab in Graves’ disease. Eur J Endocrinol 2008; 159: 515-6.

  30. El Fassi D, Nielsen CH, Bonnema SJ, Hasselbalch HC, Hegedüs L. B lymphocyte depletion with the monoclonal antibody rituximab in Graves’ Disease: A Controlled Pilot Study. J Clin Endocrinol Metab 2007; 92: 1769-72.

  31. El Fassi D, Banga JP, Gilbert JA, Padoa C, Hegedüs L, et al. Treatment of Graves’ disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol 2009; 130: 252-8.

  32. Salvi M, Vannucchi G, Campi I, Curro N, Dazzi D, et al. Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 2007; 156: 33-40.

  33. Nielsen JF, El Fassi D, Nielsen CH, Hegedüs L, Lauer SA, et al. Evidence of orbital B and T cell depletion after rituximab therapy in Graves’ ophthalmopathy. Act Ophthalmol 2009; 87(8): 927-9.

  34. Trial of rituximab for Graves’ ophthalmopathy. Available from: www.clinicaltrials.gov [ID: NCT00595335].

  35. Abraham P, Acharya S. Current and emerging treatment options for Graves’ hyperthyroidism. Ther Clin Risk Manag 2010; 6: 29-40.




2020     |     www.medigraphic.com